Teladoc Health Sees Unusually High Options Volume (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) was the target of unusually large options trading on Friday. Investors purchased 18,240 call options on the stock. This is an increase of 53% compared to the typical volume of 11,885 call options.

Teladoc Health Trading Up 2.8%

Shares of Teladoc Health stock traded up $0.23 on Friday, reaching $8.13. 2,526,852 shares of the company’s stock were exchanged, compared to its average volume of 5,518,275. The company has a market capitalization of $1.47 billion, a P/E ratio of -8.39 and a beta of 2.14. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.77. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The firm’s 50-day moving average is $6.83 and its two-hundred day moving average is $6.24.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The company had revenue of $613.85 million for the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm’s revenue was down 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Sell-side analysts predict that Teladoc Health will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TDOC has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research note on Thursday, February 26th. Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, March 10th. JPMorgan Chase & Co. cut their price target on shares of Teladoc Health from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, March 13th. BMO Capital Markets decreased their price target on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a report on Thursday, February 26th. Finally, Leerink Partners lowered their price objective on Teladoc Health from $8.50 to $5.50 and set a “market perform” rating for the company in a research report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.43.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 19,132 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the sale, the chief executive officer owned 389,894 shares in the company, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the sale, the insider directly owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. The trade was a 9.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,870 shares of company stock valued at $302,507 over the last 90 days. 0.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors have recently made changes to their positions in the stock. Essential Partners LLC acquired a new stake in shares of Teladoc Health in the 1st quarter valued at about $113,000. Janus Henderson Group PLC boosted its holdings in Teladoc Health by 7.7% in the first quarter. Janus Henderson Group PLC now owns 262,215 shares of the health services provider’s stock worth $1,429,000 after acquiring an additional 18,679 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Teladoc Health by 694.5% in the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after acquiring an additional 4,945 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Teladoc Health by 61.2% during the first quarter. California State Teachers Retirement System now owns 274,441 shares of the health services provider’s stock valued at $1,496,000 after acquiring an additional 104,160 shares in the last quarter. Finally, Quantinno Capital Management LP increased its holdings in shares of Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after acquiring an additional 1,471,631 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.